A Phase 3, multicenter, randomized, open-label, study evaluating the efficacy and safety of nanvuranlat in patients with previously treated advanced biliary tract cancer.
Study#: i3375
Contact Us: For information about this clinical study, Email Us.
Our practice complies with the Office for Civil Rights and does not discriminate based on race, color, national origin, sex, age or disability. View the notice by clicking here.
Comprehensive Cancer Centers of Nevada is helping patients by providing state-of-the-art treatment through clinical research studies. Learn More.
